CNTB
Connect Biopharma Holdings Limited
Biotechnology
Market Cap$130M
5Y Perf.-87.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CNTB vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-62.5%
CNTB vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CNTB | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $130M | $1712.35T |
| Revenue (TTM) | $26M | $0.00 |
| Net Income (TTM) | $-57M | $-168M |
| Gross Margin | 95.6% | — |
| Operating Margin | -223.4% | — |
| Total Debt | $178K | $22M |
| Cash & Equiv. | $78M | $194M |
CNTB vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CNTB
DBVT
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Connect Biopharma H… (CNTB) | 100 | 12.6 | -87.4% |
| DBV Technologies S.… (DBVT) | 100 | 37.5 | -62.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CNTB vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CNTB leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. DBV Technologies S.A. is the stronger pick specifically for profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
CNTB
Connect Biopharma Holdings Limited
The Growth Play
CNTB carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- EPS growth 74.1%
- Lower volatility, beta -0.14, Low D/E 0.2%, current ratio 11.46x
- Beta -0.14, current ratio 11.46x
Best for: growth exposure and sleep-well-at-night
DBVT
DBV Technologies S.A.
The Long-Run Compounder
DBVT is the clearest fit if your priority is long-term compounding.
- -87.0% 10Y total return vs CNTB's -87.4%
- 0.3% margin vs CNTB's -220.1%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CNTB | 72.2% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs CNTB's -220.1% |
| Stability / Safety | CNTB | Lower D/E ratio (0.2% vs 12.8%) |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CNTB | +191.3% vs DBVT's +110.4% |
| Efficiency (ROA) | CNTB | -69.4% ROA vs DBVT's -89.0% |
CNTB vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
CNTB vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCNTBLAGGINGDBVT
DBVTDBV Technologies S.A.
1leads
CNTBConnect Biopharma Hol…
1leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CNTB6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CNTB and DBVT operate at a comparable scale, with $26M and $0 in trailing revenue.
| Metric | CNTBConnect Biopharma… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $26M | $0 |
| EBITDAEarnings before interest/tax | -$57M | -$112M |
| Net IncomeAfter-tax profit | -$57M | -$168M |
| Free Cash FlowCash after capex | -$54M | -$151M |
| Gross MarginGross profit ÷ Revenue | +95.6% | — |
| Operating MarginEBIT ÷ Revenue | -2.2% | — |
| Net MarginNet income ÷ Revenue | -2.2% | — |
| FCF MarginFCF ÷ Revenue | -2.1% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -99.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -2.6% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — CNTB and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | CNTBConnect Biopharma… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $130M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $51M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -8.32x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 4.97x | — |
| Price / BookPrice ÷ Book value/share | 1.40x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — CNTB and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
CNTB leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
CNTB delivers a -80.4% return on equity — every $100 of shareholder capital generates $-80 in annual profit, vs $-130 for DBVT. CNTB carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), CNTB scores 5/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | CNTBConnect Biopharma… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -80.4% | -130.2% |
| ROA (TTM)Return on assets | -69.4% | -89.0% |
| ROICReturn on invested capital | -3.4% | — |
| ROCEReturn on capital employed | -23.2% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.00x | 0.13x |
| Net DebtTotal debt minus cash | -$78M | -$172M |
| Cash & Equiv.Liquid assets | $78M | $194M |
| Total DebtShort + long-term debt | $178,000 | $22M |
| Interest CoverageEBIT ÷ Interest expense | -5993.94x | -189.82x |
CNTB leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — CNTB and DBVT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $1,500 for CNTB. Over the past 12 months, CNTB leads with a +191.3% total return vs DBVT's +110.4%. The 3-year compound annual growth rate (CAGR) favors CNTB at 25.5% vs DBVT's 6.2% — a key indicator of consistent wealth creation.
| Metric | CNTBConnect Biopharma… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | -7.5% | +4.9% |
| 1-Year ReturnPast 12 months | +191.3% | +110.4% |
| 3-Year ReturnCumulative with dividends | +97.5% | +19.7% |
| 5-Year ReturnCumulative with dividends | -85.0% | -69.1% |
| 10-Year ReturnCumulative with dividends | -87.4% | -87.0% |
| CAGR (3Y)Annualised 3-year return | +25.5% | +6.2% |
Evenly matched — CNTB and DBVT each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CNTB and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
CNTB is the less volatile stock with a -0.14 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs CNTB's 61.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CNTBConnect Biopharma… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.14x | 1.26x |
| 52-Week HighHighest price in past year | $3.82 | $26.18 |
| 52-Week LowLowest price in past year | $0.70 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +61.0% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 42.8 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 272K | 252K |
Evenly matched — CNTB and DBVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CNTB as "Buy" and DBVT as "Buy". Consensus price targets imply 286.3% upside for CNTB (target: $9) vs 131.8% for DBVT (target: $46).
| Metric | CNTBConnect Biopharma… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $9.00 | $46.33 |
| # AnalystsCovering analysts | 5 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
DBVT leads in 1 of 6 categories (Income & Cash Flow). CNTB leads in 1 (Profitability & Efficiency). 3 tied.
Best OverallConnect Biopharma Holdings … (CNTB)Leads 1 of 6 categories
Loading custom metrics...
CNTB vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CNTB or DBVT a better buy right now?
Analysts rate Connect Biopharma Holdings Limited (CNTB) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CNTB or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 1%, compared to -85. 0% for Connect Biopharma Holdings Limited (CNTB). Over 10 years, the gap is even starker: DBVT returned -87. 0% versus CNTB's -87. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CNTB or DBVT?
By beta (market sensitivity over 5 years), Connect Biopharma Holdings Limited (CNTB) is the lower-risk stock at -0.
14β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately -1009% more volatile than CNTB relative to the S&P 500. On balance sheet safety, Connect Biopharma Holdings Limited (CNTB) carries a lower debt/equity ratio of 0% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — CNTB or DBVT?
On earnings-per-share growth, the picture is similar: Connect Biopharma Holdings Limited grew EPS 74.
1% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CNTB or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -60. 0% for Connect Biopharma Holdings Limited — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -86. 2% for CNTB. At the gross margin level — before operating expenses — CNTB leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CNTB or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CNTB or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Connect Biopharma Holdings Limited (CNTB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
14)). Both have compounded well over 10 years (CNTB: -87. 4%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CNTB and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.